Sun Pharma withdraws suit filed by Ranbaxy against USFDA

Sun Pharma withdraws suit filed by Ranbaxy against USFDA

The lawsuit challenged FDA's revocation of Ranbaxy's tentative approvals for its generic versions of Nexium and Valcyte in the US.

Strides Arcolab shares up 4% on Sun Pharma deal

Shares of Strides Arcolab rose by 4 percent Monday as it entered into a pact with Sun Pharma to buy from it erstwhile Ranbaxy's two divisions in central nervous system (CNS) segment in India for Rs 165 crore.

 

Sun Pharma to sell Ranbaxy's 2 CNS divisions to Strides for Rs 165 crore

Sun Pharma to sell Ranbaxy's 2 CNS divisions to Strides for Rs 165 crore

Sun Pharmaceutical Industries Ltd is selling erstwhile Ranbaxy's two divisions in central nervous system (CNS) segment in India to Strides Arcolab for Rs 165 crore.

 

Nifty tumbles 74 points on frantic selling; pharma stocks tank

The broader 50-share NSE Nifty opened higher at 8,601.50 and fluctuated between a high of 8,646.75 and low of 8,517.90 before ending at 8,529.45, a sharp fall of 74 points, or 0.86 percent.

Sun Pharma asks 18 top brass of Ranbaxy to resign

This comes after a year after the Dilip Shanghvi-led firm acquired Ranbaxy in an all-stock deal and the company's Q4 profits shrank 44 per cent due to costs incurred in assimilating the buyout.

Focus on getting Ranbaxy's plants USFDA nod one at a time: Sun Pharma

The Mumbai-based drug major, which acquired Ranbaxy in a USD 4 billion deal, feels it is important for the merged entity to "re-establish" the trust between Ranbaxy and the US Food and Drug Administration (USFDA).

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

The company, which had forayed into the growing Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, sold over 21 crore shares in Sun Pharma.

Sun Pharma shares tank 11% as Daiichi completes exit

Shares of Sun Pharmaceutical on Tuesday plunged nearly 11 percent after Japan's Daiichi Sankyo announced selling its entire holding in the Indian drug major for an estimated Rs 20,420 crore.

Sun Pharma slumps most in near six years on Daiichi's share sale

Shares of Sun Pharmaceutical Industries Ltd slumped as much as 10.9 percent on Tuesday, heading towards their biggest daily fall since June 2009 after Japan`s Daiichi Sankyo Co Ltd started selling its stake in the Indian drugmaker.

Sensex surges 302 points; logs 1st weekly gain in three weeks

The 50-share NSE Nifty also rose by 95.25 points or 1.12 percent, to 8,586.25 after hitting today's high of 8,603.40.

BSE to discontinue trading in Ranbaxy from April 6

The BSE has decided to delist Ranbaxy scrip from S&P BSE 100, S&P BSE 200, S&P BSE 500, S&P BSE Healthcare and S&P BSE Carbonex indices from April 6.

Sun Pharma, Ranbaxy rise after regulatory nods for merger deal

At the end of today's trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 percent and Ranbaxy Laboratories closed at Rs 819.55 apiece, up 1.86 percent.

Sun Pharma, Ranbaxy rise after regulatory nods for merger deal

Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories today settled in the positive territory after regulatory nods paved the way for completion of their USD 4-billion merger.

Sun-Ranbaxy deal gets final CCI nod; Emcure to buy 7 brands

Sun Pharma and Ranbaxy have got approval from the Competition Commission for sale of seven brands to Emcure Pharma to comply with the fair trade watchdog's conditional nod for their USD 4-billion merger.

CAG blames I-T Dept for Rs 1348 cr tax loss in pharma sector

Coming down heavily on the I-T Department, CAG has said non-compliance of procedures for giving incentives to pharmaceutical firms, including Ranbaxy, Dr Reddy's and Piramal, resulted Rs 1,348.44 crore loss to the exchequer.

Ranbaxy loses approvals, exclusivity of 2 drugs in US

Ranbaxy Laboratories' tentative approvals for its generic versions of digestive disorder drug Nexium and antiviral Valcyte along with 180-days marketing exclusivity stands canceled following a US court decision.

Ranbaxy loses approvals, exclusivity of 2 drugs in US

The DC Federal Court in the US has upheld the decision of the USFDA for rescinding tentative approvals given to it for generic digestive disorder drug Nexium and antiviral Valcyte.

Ranbaxy, Sun Pharma hit 52-week highs

Stocks of Ranbaxy climbed 3.46 percent to Rs 728 -- its one-year peak on the BSE.

Ranbaxy Q3 net loss widens to Rs 1,029.72 cr

Ranbaxy Q3 net loss widens to Rs 1,029.72 cr

The company had posted a net loss of Rs 158.94 crore during the October-December period of previous fiscal.

Ranbaxy forfeits 180 days exclusivity for stomach drugs

Drug major Ranbaxy on Tuesday said that the US health regulator has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets.